CIBC initiated coverage on shares of Personalis (NASDAQ:PSNL) in a research note released on Monday, FirstToMarketsRatingsTable reports. The brokerage issued an outperform rating and a $29.00 target price on the stock.

Several other brokerages also recently issued reports on PSNL. Morgan Stanley set a $70.00 price target on shares of Edison International and gave the company a hold rating in a report on Monday. Cowen reissued a buy rating on shares of Avrobio in a report on Monday. Oppenheimer set a $110.00 price target on shares of Medtronic and gave the company a buy rating in a report on Monday. Finally, Bank of America set a $68.00 price target on shares of Inphi and gave the company a buy rating in a report on Monday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Personalis has an average rating of Buy and a consensus target price of $28.25.

Shares of PSNL stock opened at $20.31 on Monday. Personalis has a 12-month low of $21.73 and a 12-month high of $31.88.

In other news, Director Ken Ludlum purchased 70,000 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average cost of $17.00 per share, with a total value of $1,190,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Story: What is a dead cat bounce?

Analyst Recommendations for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with's FREE daily email newsletter.